Perspectives on benefits and risks of creation of an “injection drug use” billing code

Larson ME, Pan Y, Lakhani F, Chavez J, Santana A, Nogueira NF, Lieberman A, Riley ED, Wu KC, Tien P, Kizer J, Floris-Moore M, Pyslar[...]

Morinishi CD, Brown CE, Younes R. Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A[...]

Livorsi DJ, Merchant J, Cho H, Goetz MB, Alexander B, Goto M. Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant[...]